Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dTDP-L-rhamnose biosynthesis enzymes comprise a conserved four-step metabolic pathway—consisting of RmlA, RmlB, RmlC, and RmlD—responsible for synthesizing dTDP-L-rhamnose from glucose-1-phosphate and dTTP (Giraud & Naismith, 2000, Current Opinion in Structural Biology). This nucleotide sugar serves as a critical precursor for the assembly of the bacterial cell wall, O-antigens, and capsular polysaccharides in many significant human pathogens, including Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Streptococcus pneumoniae (van der Beek et al., 2019, Nature Communications). Because the L-rhamnose biosynthetic pathway is essential for bacterial viability and virulence but is entirely absent in humans and other mammals, these enzymes are highly prioritized as targets for the development of novel, narrow-spectrum antibiotics (Mistou et al., 2016, Journal of Biological Chemistry). Inhibition of any enzyme in the pathway, particularly the epimerase RmlC or the reductase RmlD, results in defective cell wall construction, increased susceptibility to host immune responses, and reduced pathogenicity (Dong et al., 2007, Journal of Molecular Biology). While several experimental small-molecule inhibitors and substrate analogs have been identified through high-throughput screening and structure-based drug design, no therapeutic agents targeting this pathway have yet reached clinical approval (Sivayoganathan et al., 2021, Antibiotics). The specificity of these enzymes to bacteria offers a significant therapeutic window, potentially minimizing off-target effects in human patients while addressing the growing challenge of multi-drug resistant infections.
Inhibition of the sequential enzymatic steps (RmlA through RmlD) prevents the production of dTDP-L-rhamnose, leading to the depletion of essential cell wall components, loss of structural integrity, and attenuation of bacterial virulence.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on dTDP-L-rhamnose biosynthesis enzymes (Rml pathway enzymes).